Skip to content
Main menu
Toggle navigation
Logo on scroll
Home
About
Company History
Leadership Team
Our Board
Research & Technology
Overview
Chemotherapy & OncoSil™
Indications
OncoSil™ Implant
Implant Aftercare
Radiation Safety Aspects
About Clinical Trials
Clinical Studies
Becoming an OncoSil™ Trial Centre
Important Risk Information
FAQ
Investor Centre
Overview
ASX Announcements
Analyst Reports
Annual Reports
Events & Presentations
Subscribe to Updates
Corporate Governance
Media Coverage
Contact Us
Analyst Reports
2018 REPORTS
2018 Sep 10 - Bell Potter
2018 Apr 16 - Wilsons - Cash & Clinical data behind them now
2018 Mar 8 - Bell Poter - Flash Note
2018 Mar 6 - Wilsons - BUY Disease control rates
2017 reports
2017 Oct 24 - Wilsons - CT Scans indicate good progress
2017 Oct 23 - Wilsons - Positive early Oncopac-1 data
2017 Oct 23 - Bell Potter - First Glimpse at Efficacy
2017 Aug 9 - Wilsons - Oncopac-1 trial progress
2017 Aug 1 - Bell Potter - 10 centres now recruiting
2017 April 3 - first patient enrolled in the Oncopac 1 trial
2017 March 28 - Bell Potter - Enrolment Commences
2016 REPORTS
2016 Nov 9 - Bell Potter - OncoPac-1 commence recruitment
2016 Aug 3 - Wilsons - IDE Trial approval sets scene for evidence
2016 Aug 2 - Bell Potter - One Giant Step for Oncosil
2016 Jun 17 - Wilsons - Thoughts on regulatory situation and outlook
2016 Mar 21 - Bell Potter - OSL Initiation
2016 Feb 17 - Wilsons - Oncosil takes the money ahead of key milestones
2016 Jan 21 - Wilsons - Oncosil Medical Research update
2015 reports
2015 Oct 15 - Wilsons - On the cusp in Europe
2015 Oct 01 - Van Leeuwenhoeck - Initiating Oncosil Coverage
2015 Oct 06 - Wilsons - Great time to develop new brachytherapy devices
2014 REPORTS
2014 Mar 19 - Taylor Collison - Oncosil Research Report
2014 Mar 17 - Baillieu Holst - Oncosil Research Report
